FDA Seeks Approval for Tobacco Research Industry Discussions
Published Date: 9/19/2025
Notice
Summary
The FDA is asking for approval to collect info from meetings with tobacco product makers and researchers. This helps keep tabs on new tobacco product research and development. If approved, it won’t cost businesses extra money but will keep things clear and organized.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA collects tobacco R&D meeting info
The FDA is asking OMB to approve collecting information from meetings with tobacco product makers and researchers so it can track new tobacco product research and development. The notice says that if OMB clears the collection under the Paperwork Reduction Act, it will not impose extra costs on businesses and will help keep records clear and organized.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12167 — Andrew Jonathan Morgan: Final Debarment Order
Andrew Jonathan Morgan is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on June 17, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping things safe and legal.
2026-12165 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Previous / Next Documents
Previous: 2025-18183 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request, Exemptions From Substantial Equivalence Requirements for Tobacco Products
The FDA is asking for approval to collect info about tobacco products that don’t need to prove they’re similar to existing ones. This affects tobacco companies who want to skip some usual rules, saving them time and paperwork. The review is happening now, so companies should stay tuned for updates that might impact their costs and deadlines.
Next: 2025-18185 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Southern Hemisphere Influenza Virus Vaccines; Center for Biologics Evaluation and Research (CBER) Allergen Standardization Program
The FDA is hosting a public meeting with experts to talk about flu vaccines for the Southern Hemisphere and allergen standards. They want your thoughts too, so they’ve opened a public comment period. This affects vaccine makers, health pros, and anyone interested in safer, better vaccines, with no big costs but important timing to join the conversation.